Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04709094 · ClinicalTrials.gov registry record · Phase 1
A Drug Interaction Study of Danicopan
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT04709094 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT04709094, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This was a 3-part study (Part 1, Part 2, Part 3) with each part being an open-label, fixed sequence, 2-period study in healthy adult participants.
Interventions
- DRUG Bupropion
- DRUG Warfarin
- DRUG Danicopan
- DRUG Ethinyl Estradiol/Norethindrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-07-28 |
| Est. Completion | 2020-04-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04709094
The ClinicalTrials.gov registry entry for NCT04709094 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bupropion is the first listed.
NCT04709094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04709094 about?
NCT04709094 is a clinical study titled "A Drug Interaction Study of Danicopan". This was a 3-part study (Part 1, Part 2, Part 3) with each part being an open-label, fixed sequence, 2-period study in healthy adult participants.
What is the current status of trial NCT04709094?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2019-07-28. Estimated completion is 2020-04-17.
What interventions are being tested in trial NCT04709094?
The interventions under investigation include: Bupropion (DRUG), Warfarin (DRUG), Danicopan (DRUG), Ethinyl Estradiol/Norethindrone (DRUG).
Who is sponsoring clinical trial NCT04709094?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.